Alan Boddy

Research Interests

Cancer Therapy Clinical Pharmacology and Therapeutics Pharmacogenomics Pharmacology and Pharmaceutical Sciences

Prof Alan Boddy

Professor

School of Pharmacy and Biomedical Science

College of Health

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.

After a PhD and post-doctoral training in Manchester, Alan spent a period at the University of Washington before returning to the UK to focus on cancer therapy and the role of pharmacokinetics and pharmacology more generally. In Newcastle upon Tyne he established an internationally-recognised group working on the pharmacology of drugs in early phase clinical trials, pharmacology in children with cancer and pharmacogenetics.
He was instrumental in implementing quality control standards for academic-led studies in the UK, in conjunction with Cancer Research UK and the MHRA, and led an EU-funded international study on off-patent medicines in children.  Alan also founded an online MSc course in Oncology and Palliative care that provided the model for online teaching at the University of Newcastle and led training workshops for clinicians and nurses on the principles of cancer pharmacology. 
Moving to Sydney in 2014, he continued these interests, establishing links with the Melanoma Institute of Australia, Westmead Hospital and the Children’s Cancer Institute. Alan has published more than 150 peer-reviewed articles, in addition to reviews and book chapters and has supervised over 30 post-graduate students and clinical fellows.  
Alan was appointed Head of School, Pharmacy and Medical Sciences at UniSA in July 2018 and became Dean of Research, Clinical and Health Sciences in April 2020.

Date Position Institution name
2014 - 2018 Professor of Cancer Pharmacology University of Sydney
2006 - 2014 Professor of Cancer Pharmcology Newcastle University

Date Institution name Country Title
1983 - 1986 University of Manchester United Kingdom PhD
1979 - 1982 University of Manchester United Kingdom BSc (Hons)

Year Citation
2025 Iland, H. J., Reynolds, J., Boddy, A., Schultz, H. B., & Wei, A. H. (2025). ALLG APML5: Bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL. Blood Advances, 9(6), 1476-1484.
DOI
2025 Sandhu, G., Adattini, J., Armstrong Gordon, E., O'Neill, N., Boddy, A. V., & Ward, R. L. (2025). Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice. eClinical Medicine, 82(103161), 1-11.
DOI Scopus1 Europe PMC3
2023 Chan, W. J. J., Adiwidjaja, J., McLachlan, A. J., Boddy, A. V., & Harnett, J. E. (2023). Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance. Cancer Chemotherapy and Pharmacology, 91(2), 103-119.
DOI
2022 Adiwidjaja, J., Gross, A. S., Boddy, A. V., & McLachlan, A. J. (2022). Physiologically-based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimens. British Journal of Clinical Pharmacology, 88(4), 1735-1750.
DOI
2022 Adiwidjaja, J., Adattini, J. A., Boddy, A. V., & McLachlan, A. J. (2022). Physiologically based pharmacokinetic modeling approaches for patients with SARS-CoV-2 infection: a case study with imatinib. The Journal of Clinical Pharmacology, 62(10), 1285-1296.
DOI
2022 Modi, N. D., Abuhelwa, A. Y., Mckinnon, R. A., Boddy, A. V., Haseloff, M., Wiese, M. D., . . . Hopkins, A. M. (2022). Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration. JAMA Oncology, 8(9), 1310-1316.
DOI Scopus17 Europe PMC17
2022 Adiwidjaja, J., Boddy, A. V., & McLachlan, A. J. (2022). Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib. European Journal of Clinical Pharmacology, 78(4), 597-611.
DOI
2021 Sallustio, B. S., & Boddy, A. V. (2021). Is there scope for better individualisation of anthracycline cancer chemotherapy?. British Journal of Clinical Pharmacology, 87(2), 295-305.
DOI Scopus29 WoS30 Europe PMC26
2020 Liu, X., Low, S. K., Atkins, J. R., Wu, J. Q., Reay, W. R., Cairns, H. M., . . . Cairns, M. J. (2020). Wnt receptor gene FZD1 was associated with schizophrenia in genome-wide SNP analysis of the Australian Schizophrenia Research Bank cohort. Australian and New Zealand Journal of Psychiatry, 54(9), 902-908.
DOI Scopus9 Europe PMC10
2020 Hellmann, F., Voller, S., Krischke, M., Jamieson, D., Andre, N., Bisogno, G., . . . Hempel, G. (2020). Genetic polymorphisms affecting cardiac biomarker concentrations in children with cancer: an analysis from the 'European Paediatric Oncology off-patents Medicines Consortium' (EPOC) trial. European Journal of Drug Metabolism and Pharmacokinetics, 45(3), 413-422.
DOI
2020 Adiwidjaja, J., Boddy, A. V., & McLachlan, A. J. (2020). Implementation of a physiologically based pharmacokinetic modeling approach to guide optimal dosing regimens for imatinib and potential drug interactions in paediatrics. Frontiers in Pharmacology, 10(1672), 1-18.
DOI
2020 Adiwidjaja, J., Boddy, A. V., & Mclachlan, A. J. (2020). Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically‐based pharmacokinetic modelling approach. British Journal of Clinical Pharmacology, 86(10), 2080-2094.
DOI
2020 Adiwidjaja, J., Boddy, A. V., & McLachlan, A. J. (2020). Physiologically-based pharmacokinetic predictions of the effect of curcumin on metabolism of imatinib and bosutinib: in vitro and in vivo disconnect. Pharmaceutical Research, 37(7, article no. 128), 1-16.
DOI
2020 Xie, J., Span, M., van Maarseveen, E., Langenhorst, J., Boddy, A. V., Sia, K. C. S., . . . Lock, R. B. (2020). Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia. Pediatric blood and cancer, 67(4, article no 28133), 1-10.
DOI
2019 Kim, H. Y., Duong, J. K., Gonzalez, M., Long, G. V., Menzies, A. M., Rizos, H., . . . Boddy, A. V. (2019). Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. Cancer Chemotherapy and Pharmacology, 83(4), 693-704.
DOI
2019 Shafiei, M., Yoon, R., McLachlan, A., Boddy, A., Beale, P., & Blinman, P. (2019). Pharmacokinetics of anticancer drugs used in treatment of older adults with colorectal cancer: a systematic review. Therapeutic drug monitoring, 41(5), 553-560.
DOI
2019 Duong, J. K., Veal, G. J., Nath, C. E., Shaw, P. J., Errington, J., Ladenstein, R., & Boddy, A. V. (2019). Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. British journal of clinical pharmacology, 85(1), 136-146.
DOI
2019 Adiwidjaja, J., Boddy, A. V., & McLachlan, A. J. (2019). Physiologically based pharmacokinetic modelling of hyperforin to predict drug interactions with St John's wort. Clinical pharmacokinetics, 58(7), 911-926.
DOI
2019 Kim, H. Y., Upadhyay, P. J., Fahmy, A., Liu, X., Duong, J. K., & Boddy, A. V. (2019). Clinical pharmacokinetic and pharmacodynamic considerations in the (modern) treatment of melanoma. Clinical pharmacokinetics, 58(8), 1029-1043.
DOI Scopus9 Europe PMC4
2018 White Koning, M., Osborne, C., Paci, A., Boddy, A. V., Chatelut, E., & Veal, G. J. (2018). Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence. European journal of cancer, 91, 56-67.
DOI
2018 Adiwidjaja, J., Boddy, A. V., & McLachlan, A. J. (2018). A strategy to refine the phenotyping approach and its implementation to predict drug clearance: a physiologically‐based pharmacokinetic simulation study. CPT: pharmacometrics & systems pharmacology, 7(12), 798-808.
DOI
2017 Kim, H. Y., Martin, J. H., McLachlan, A. J., & Boddy, A. V. (2017). Precision dosing of targeted anticancer drugs-challenges in the real world. Translational cancer research, 6(S10), S1500-S1511.
DOI
2017 Adiwidjaja, J., McLachlan, A. J., & Boddy, A. V. (2017). Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions. Expert opinion on drug metabolism and toxicology, 13(9), 953-972.
DOI
2017 Duong, J. K., Griffin, M. J., Hargrave, D., Vormoor, J., Edwards, D., & Boddy, A. V. (2017). A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia. British journal of clinical pharmacology, 83(8), 1713-1722.
DOI
2017 Park, J. J., Boddy, A. V., Liu, X., Harris, D., Lee, V., Kefford, R. F., & Carlino, M. S. (2017). Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis. Pigment cell & melanoma research, 30(1), 68-71.
DOI
2017 Völler, S., Hempel, G., Würthwein, G., Boddy, A. V., Krischke, M., Andre, N., . . . Boos, J. (2017). Towards a model-based dose recommendation for doxorubicin in children. Clinical pharmacokinetics, 56(3), 215-223.
DOI
2017 Jamieson, D., Sunter, N., Muro, S., Pouche, L., Cresti, N., Lee, J., . . . Boddy, A. V. (2017). Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide. European journal of cancer, 71, 15-24.
DOI
2017 Fresneau, B., Hackshaw, A., Hawkins, D. S., Paulussen, M., Anderson, J. R., Judson, I., . . . Le Teuff, G. (2017). Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study). Pediatric blood & cancer, 64(8, article no. e26457), 1-8.
DOI
2017 Vormoor, B., Veal, G. J., Griffin, M. J., Boddy, A. V., & Vormoor, J. (2017). A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatric blood & cancer, 64(6, article no. e26351), 1-4.
DOI
2016 Liu, X., Low, S. K., & Boddy, A. V. (2016). The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors. Expert opinion on drug metabolism and toxicology, 12(8), 851-863.
DOI
2016 Dent, B. M., Ogle, L. F., O'Donnell, R. L., Hayes, N., Malik, U., Curtin, N. J., . . . Jamieson, D. (2016). High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. International journal of cancer, 138(1), 206-216.
DOI
2016 Drew, Y., Ledermann, J., Hall, G., Rea, D., Glasspool, R., Highley, M., . . . Plummer, R. (2016). Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. British journal of cancer, 114(7), 723-730.
DOI
2016 Krischke, M., Hempel, G., Völler, S., André, N., D'Incalci, M., Bisogno, G., . . . Boos, J. (2016). Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial. Cancer chemotherapy and pharmacology, 78(6), 1175-1184.
DOI
2016 Pu, X., Storr, S. J., Ahmad, N. S., Chan, S. Y., Moseley, P. M., Televantou, D., . . . Martin, S. G. (2016). Calpain-1 is associated with adverse relapse free survival in breast cancer: a confirmatory study. Histopathology, 68(7), 1021-1029.
DOI
2016 Cresti, N., Lee, J., Rourke, E., Televantou, D., Jamieson, D., Verrill, M., & Boddy, A. V. (2016). Genetic variants in the HER2 gene: influence on HER2 overexpression and loss of heterozygosity in breast cancer. European journal of cancer, 55, 27-37.
DOI
2016 Jamieson, D., Griffin, M. J., Sludden, J., Drew, Y., Boddy, A. V., & Plummer, R. (2016). A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European journal of cancer, 68, 1-10.
DOI
2016 Green, M. H., Ford, J. L., Oxley, A., Green, J. B., Park, H., Berry, P., . . . Lietz, G. (2016). Plasma retinol kinetics and β-carotene bioefficacy are quantified by model-based compartmental analysis in healthy young adults with low vitamin A stores. Journal of nutrition, 146(10), 2129-2136.
DOI
2016 Green, M. H., Ford, J. L., Green, J. B., Berry, P., Boddy, A. V., Oxley, A., & Lietz, G. (2016). A retinol Isotope dilution equation predicts both group and individual total body vitamin A stores in adults based on data from an early postdosing blood sample. Journal of nutrition, 146(10), 2137-2142.
DOI
2016 Veal, G. J., Cole, M., Chinnaswamy, G., Sludden, J., Jamieson, D., Errington, J., . . . Boddy, A. V. (2016). Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma. European journal of cancer, 55, pp. 56-64, 56-64.
DOI
2016 Walsh, C., Bonner, J. J., Johnson, T. N., Neuhoff, S., Ghazaly, E. A., Gribben, J. G., . . . Veal, G. J. (2016). Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer. British journal of clinical pharmacology, 81(5), 989-998.
DOI
2016 Goulooze, S. C., Galettis, P., Boddy, A. V., & Martin, J. H. (2016). Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours. Cancer chemotherapy and pharmacology, 78(1), 209-216.
DOI
2016 Ogle, L. F., Orr, J. G., Willoughby, C. E., Hutton, C., McPherson, S., Plummer, R., . . . Reeves, H. L. (2016). Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for hepatocellular carcinoma?. Journal of hepatology, 65(2), 305-313.
DOI
2015 Parrish, K. E., Cen, L., Murray, J., Calligaris, D., Kizilbash, S., Mittapalli, R. K., . . . Sarkaria, J. N. (2015). Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts Is limited by ineffective drug penetration into the central nervous system. Molecular cancer therapeutics, 14(12), 2735-2743.
DOI
2015 Moreno, L., Marshall, L. V., Pearson, A. D. J., Morland, B., Elliott, M., Campbell Hewson, Q., . . . Hargrave, D. (2015). A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clinical cancer research, 21(2), 267-273.
DOI Europe PMC41
2015 Kim, S. Y., Naskar, D., Kundu, S. C., Bishop, D. P., Doble, P. A., Boddy, A. V., . . . Chrzanowski, W. (2015). Formulation of biologically-inspired silk-based drug carriers for pulmonary delivery targeted for lung cancer. Scientific reports, 5(11878), 1-13.
DOI
2015 Voeller, S., Boos, J., Krischke, M., Wuerthwein, G., Kontny, N. E., Boddy, A. V., & Hempel, G. (2015). Age-dependent pharmacokinetics of doxorubicin in children with cancer. Clinical pharmacokinetics, 54(11), 1139-1149.
DOI
2014 Jamieson, D., Lee, J., Cresti, N., Jackson, R., Griffin, M., Sludden, J., . . . Boddy, A. V. (2014). Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil. Cancer chemotherapy and pharmacology, 74(4), 667-674.
DOI
2014 Oxley, A., Berry, P., Taylor, G., Cowell, J., Hall, M. J., Hesketh, J., . . . Boddy, A. V. (2014). An LC/MS/MS method for stable isotope dilution studies of β-carotene bioavailability, bioconversion, and vitamin A status in humans. Journal of lipid research, 55(2), 319-328.
DOI
2014 Murray, J., Thomas, H., Berry, P., Kyle, S., Patterson, M., Jones, C., . . . Curtin, N. J. (2014). Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. British journal of cancer, 110(8), 1977-1984.
DOI
2014 Hill, C. R., Cole, M., Errington, J., Malik, G., Boddy, A. V., & Veal, G. J. (2014). Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer. Clinical pharmacokinetics, 53(8), 741-751.
DOI
2014 Krischke, M., Boddy, A. V., & Boos, J. (2014). Sources of preanalytical error in pharmacokinetic analyses - focus on intravenous drug administration and collection of blood samples. Expert opinion on drug metabolism & toxicology, 10(6), 825-838.
DOI
2013 Hill, C. R., Jamieson, D., Thomas, H. D., Brown, C. D. A., Boddy, A. V., & Veal, G. J. (2013). Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. Biochemical pharmacology, 85(1), 29-37.
DOI
2013 Veal, G. J., Errington, J., Rowbotham, S. E., Illingworth, N. A., Malik, G., Cole, M., . . . Boddy, A. V. (2013). Adaptive dosing approaches to the Individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clinical cancer research, 19(2), 469-479.
DOI
2013 Kontny, N. E., Wuerthwein, G., Boos, J., Boddy, A. V., Krischke, M., Fuhr, U., . . . Hempel, G. (2013). Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. Cancer chemotherapy and pharmacology, 71(3), 749-763.
DOI
2013 Boddy, A. V. (2013). Genetics of cisplatin ototoxicity: Confirming the unexplained?. Clinical Pharmacology and Therapeutics, 94(2), 198-200.
DOI
2012 Jarvis, I. W. H., Meczes, E. L., Thomas, H. D., Edmondson, R. J., Veal, G. J., Boddy, A. V., . . . Tilby, M. J. (2012). Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues. Biochemical pharmacology, 83(1), 69-77.
DOI
2012 Kontny, N. E., Boos, J., Wuerthwein, G., Hempel, G., Boddy, A. V., Groll, A. H., & Krischke, M. (2012). Minimization of the preanalytical error in pharmacokinetic analyses and therapeutic drug monitoring: focus on IV drug administration. Therapeutic drug monitoring, 34(4), 460-466.
DOI
2012 Veal, G. J., & Boddy, A. V. (2012). Chemotherapy in newborns and preterm babies. Seminars in fetal & neonatal medicine, 17(4), 243-248.
DOI
2011 Jamieson, D., & Boddy, A. V. (2011). Pharmacogenetics of genes across the doxorubicin pathway. Expert opinion on drug metabolism and toxicology, 7(10), 1201-1210.
DOI
2011 Kontny, N. E., Hempel, G., Boos, J., Boddy, A. V., & Krischke, M. (2011). Minimization of the preanalytical error in plasma samples for pharmacokinetic analyses and therapeutic drug monitoring: using doxorubicin as an example. Therapeutic drug monitoring, 33(6), 766-771.
DOI
2011 Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., . . . Nishiya, T. (2011). A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. British journal of cancer, 104(4), 593-598.
DOI
2011 Chinnaswamy, G., Errington, J., Foot, A., Boddy, A. V., Veal, G. J., & Cole, M. (2011). Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy. European journal of cancer, 47(10), 1556-1563.
DOI
2011 Pridgeon, S. W., Heer, R., Taylor, G. A., Newell, D. R., O'Toole, K., Robinson, M., . . . Boddy, A. V. (2011). Thiothymidine combined with UVA as a potential novel therapy for bladder cancer. British journal of cancer, 104(12), 1869-1876.
DOI
2011 Jamieson, D., Cresti, N., Bray, J., Sludden, J., Griffin, M. J., Hawsawi, N. M., . . . Boddy, A. V. (2011). Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenetics and genomics, 21(12), 808-819.
DOI
2011 Illingworth, N. A., Boddy, A. V., Daly, A. K., & Veal, G. J. (2011). Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. British journal of pharmacology, 162(4), 989-999.
DOI
2010 Bray, J., Sludden, J., Griffin, M. J., Cole, M., Verrill, M., Jamieson, D., & Boddy, A. V. (2010). Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British journal of cancer, 102(6), 1003-1009.
DOI
2010 Veal, G. J., Cole, M., Errington, J., Pearson, A. D. J., Gerrard, M., Gerrard, M., . . . Boddy, A. V. (2010). Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. Cancer chemotherapy and pharmacology, 65(6), 1057-1066.
DOI
2010 Rowbotham, S. E., Boddy, A. V., Redfern, C. P. F., Veal, G. J., & Daly, A. K. (2010). Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug metabolism and disposition, 38(8), 1261-1266.
DOI
2010 Daniel, R. A., Rozanska, A. L., Mulligan, E. A., Drew, Y., Thomas, H. D., Castelbuono, D. J., . . . Curtin, N. J. (2010). Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. British journal of cancer, 103(9), 1588-1596.
DOI
2010 Israels, T., Damen, C. W. N., Cole, M., van Geloven, N., Boddy, A. V., Caron, H. N., . . . Veal, G. J. (2010). Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. European journal of cancer, 46(10), 1841-1847.
DOI
2010 Rowbotham, S. E., Illingworth, N. A., Daly, A. K., Veal, G. J., & Boddy, A. V. (2010). Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans. Drug metabolism and disposition, 38(7), 1211-1217.
DOI
2009 Picton, S. V., Keeble, J., Holden, V., Errington, J., Boddy, A. V., & Veal, G. J. (2009). Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma. Cancer chemotherapy and pharmacology, 63(4), 749-752.
DOI
2009 Plummer, R., Vidal, L., Griffin, M., Lesley, M., de Bono, J., Coulthard, S., . . . Boddy, A. V. (2009). Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clinical cancer research, 15(9), 3177-3183.
DOI
2009 Jamieson, D., Cresti, N., Verrill, M. W., & Boddy, A. V. (2009). Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma. Journal of immunological methods, 345(1-2), 106-111.
DOI
2009 Cruickshank, G. S., Ngoga, D., Detta, A., Green, S., & Boddy, A. (2009). A cancer research UK pharmacokinetic study of BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT. Applied radiation and isotopes, 67(7-8, supplement), S31-S33.
DOI
2009 Daniel, R. A., Rozanska, A. L., Thomas, H. D., Mulligan, E. A., Drew, Y., Castelbuono, D. J., . . . Clifford, S. C. (2009). Inhibition of poly (ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clinical cancer research, 15(4), 1241-1249.
DOI
2008 Plummer, R., Jones, C., Middleton, M., Wilson, R., Evans, J., Olsen, A., . . . Calvert, H. (2008). Phase i study of the poly(ADP-Ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clinical cancer research, 14(23), 7917-7923.
DOI
2008 Mondick, J. T., Gibiansky, L., Gastonguay, M. R., Skolnik, J. M., Cole, M., Veal, G. J., . . . Barrett, J. S. (2008). Population pharmacokinetic investigation of actinomycin-D in children and young adults. Journal of clinical pharmacology, 48(1), 35-42.
DOI
2008 Chinnaswamy, G., Cole, M., Boddy, A. V., Keir, M., Price, L., Parry, A., . . . Veal, G. J. (2008). Estimation of renal function and its potential impact on carboplatin dosing in children with cancer. British journal of cancer, 99(6), 894-899.
DOI
2008 Plummer, R., Woll, P., Fyfe, D., Boddy, A. V., Griffin, M., Hewitt, P., . . . Verrill, M. (2008). A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies. Clinical cancer research, 14(24), 8288-8294.
DOI

Date Role Research Topic Program Degree Type Student Load Student Name
2022 Co-Supervisor - Doctor of Philosophy Doctorate Full Time Miss Deirdre Landsberg

Date Role Editorial Board Name Institution Country
2000 - ongoing Board Member Cancer Chemotherapy and Pharmacology Newcastle University United Kingdom
  • Position: Professor
  • Email: alan.boddy@adelaide.edu.au
  • Alternative Contact: For CHS matters: Belinda Crist: Executive Assistant Email: belinda.crist@unisa.edu.au Phone: 08 830 22100

Connect With Me

External Profiles

Other Links